PLSE logo

PLSE
Pulse Biosciences Inc

2,047
Mkt Cap
$1.37B
Volume
82,078.00
52W High
$26.30
52W Low
$12.56
PE Ratio
-18.71
PLSE Fundamentals
Price
$20.77
Prev Close
$20.21
Open
$20.13
50D MA
$21.04
Beta
1.37
Avg. Volume
261,776.74
EPS (Annual)
-$1.08
P/B
17.00
Rev/Employee
$3,017.24
$852.13
Loading...
Loading...
News
all
press releases
Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday
Pulse Biosciences (NASDAQ:PLSE) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-pulse-biosciences-inc-stock...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.9% - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Trading Down 7.9% - Time to Sell...
MarketBeat·20h ago
News Placeholder
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced late-breaking...
Business Wire·5d ago
News Placeholder
Pulse Biosciences nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced that its nPulse Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26...
Business Wire·10d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% Higher - Here's Why
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% Higher - Time to Buy...
MarketBeat·13d ago
News Placeholder
Pulse Biosciences to Host Analyst Event on April 25, 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago...
Business Wire·13d ago
News Placeholder
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
Zacks·17d ago
News Placeholder
Pulse Biosciences Appoints Liane Teplitsky CCO, Expands David Kenigsberg Role As Full Time CMO
(RTTNews) - Pulse Biosciences, Inc. (PLSE), a bioelectric medicine company, Thursday, announced the appointment of Liane Teplitsky as Chief Operating Officer...
Nasdaq News: Markets·21d ago
News Placeholder
Pulse Biosciences Strengthens Executive Leadership Team
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced the strengthening of its executive leadership...
Business Wire·21d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 11.7% - Here's Why
Pulse Biosciences (NASDAQ:PLSE) Trading Down 11.7% - Here's Why...
MarketBeat·23d ago
<
1
2
...
>

Latest PLSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.